These receptors have an established role in tumour-mediated NK cell activation and their inhibition by TGF-β was associated with reduced granule exocytosis, tumour killing and IFN-γ release; effector pathways that are essential for robust anti-tumour immunity [1], [37], [38]. Here, TGFB1 is linked to neoplasm.